MENU
Thursday, July 15th, 2:00 PM EDT

Lupus anticoagulants and antiphospholipid syndrome: Resolving confusion, providing new guideline updates

Sponsored by: Diagnostica Stago, Inc.
Speaker

Abstract
Lupus anticoagulants and antiphospholipid syndrome: Resolving confusion, providing new guideline updates
 

Antiphospholipid syndrome (aPS) is a thrombotic disorder characterized by persistent venous and arterial thrombosis, potentially resulting in any symptoms related to those disorders, including balance and mobility, vision problems, speech and memory, tingling sensations, transient ischemic attack, rash, or repeated migraines. While the disorder can occur in both men and women, additional obstetric or gynecological manifestations can occur in women, including miscarriage, preeclampsia, and fetal growth delays. Antiphospholipid antibodies, including lupus anticoagulant assays run on automated coagulation platforms are one part of the panel of tests recommended to screen and diagnose aPS. As a member of the Scientific and Standardization Committee on lupus anticoagulants and antiphospholipid antibodies from the International Society on Thrombosis and Heamostasis, Dr Tom Ortel will present recent guideline updates and bring together relevant clinical research publications. The presentation will educate attendees and resolve any remaining confusion present in the greater scientific community.

 
Learning Objectives
  • Present recent guideline updates on lupus anticoagulants screening and diagnostic methods
  • Illustrate recent clinical research findings recently published in peer-reviewed journals
  • Demonstrate relevant clinical cases highlighting the role of lupus anticoagulant assays in the clinical care continuum
 
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.  CE credits are available for this webinar up to 2 years from the date of the live broadcast

Connect with us